Anticoagulation Therapy with LMWH and Apixaban

Introduction to Anticoagulation Options

The American College of Chest Physicians recommends low molecular weight heparin (LMWH) at 1 mg/kg twice daily and apixaban 5 mg twice daily as effective anticoagulants for venous thromboembolism, but they are not clinically equivalent, with apixaban offering superior convenience and comparable or better safety, while LMWH remains preferred in specific populations such as cancer-associated thrombosis and severe renal impairment 1, 2

Both LMWH and apixaban demonstrate similar efficacy for treating acute venous thromboembolism, with recurrent VTE rates of approximately 2-4% in clinical trials, according to the British Thoracic Society 3
Apixaban 10 mg twice daily for 7 days followed by 5 mg twice daily is the standard regimen for DVT/PE treatment, requiring no initial parenteral anticoagulation, as recommended by the American College of Cardiology 2, 3

The American Society of Clinical Oncology recommends LMWH as the preferred agent for cancer-associated thrombosis, with enoxaparin 1 mg/kg every 12 hours or 1.5 mg/kg once daily, due to its superior efficacy and safety profile in this population 1, 2
For patients with severe renal impairment (CrCl <30 mL/min), the National Kidney Foundation recommends LMWH with anti-Xa monitoring or unfractionated heparin instead of apixaban, due to the increased risk of bleeding and accumulation of apixaban in this population 1, 2

The American Heart Association recommends weight-based dosing of LMWH, with 1 mg/kg twice daily or 1.5 mg/kg once daily, as critical for therapeutic anticoagulation, and notes that different LMWH preparations are not interchangeable due to varying molecular weights and pharmacokinetic properties 4, 6, 7
Apixaban can be started immediately at 10 mg twice daily, with a standard maintenance dose of 5 mg twice daily after day 7, and an option for dose reduction to 2.5 mg twice daily for extended therapy after 6 months, as recommended by the European Society of Cardiology 2, 1

The International Society on Thrombosis and Haemostasis recommends that LMWH generally does not require routine anti-Xa monitoring, except in obesity, renal impairment, pregnancy, or extremes of weight, while apixaban requires no routine laboratory monitoring, improving convenience and reducing healthcare costs 6, 4, 3, 2